S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer (NCT04155034)

🧪 Interventions in This Study

• Magnetic Resonance Imaging (PROCEDURE)
• Prophylactic Cranial Irradiation (RADIATION)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC)
2. Patient must have an MRI of the brain performed within 28 days prior to registration documenting no evidence of brain metastases or leptomeningeal disease. Patient also must not have a history of brain metastases or leptomeningeal disease
3. Immunotherapy concurrent with and/or adjuvant to first-line therapy is allowed at the discretion of the treating physician. Patients with limited-stage (LS)-SCLC must have completed platinum-based chemotherapy and either definitive thoracic radiotherapy (including stereotactic body radiation therapy \[SBRT\] for early-stage T1-2 N0 M0 disease who do not undergo surgery) or definitive surgical resection; thoracic radiation in addition to definitive surgical resection is allowed at the discretion of the treating physician, but is not required. Patients with extensive-stage (ES)-SCLC must have completed platinum-based chemotherapy either with or without thoracic radiotherapy at the discretion of the treating physician
4. All adverse events from prior treatment must have resolved to =\< grade 2 (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0) prior to randomization
5. Patient must have had a response to first-line therapy and no evidence of progression in opinion of the treating investigator. Systemic imaging (computed tomography \[CT\] or positron emission tomography \[PET\]/CT including the chest and abdomen) must be performed within 28 days prior to randomization
6. No more than 8 weeks may have elapsed between day 1 of the last cycle of chemotherapy and randomization
7. Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy. Patients who have undergone prior stereotactic radiosurgery for benign tumors or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis
8. Patient must have Zubrod performance status of 0-2
9. Patient must not have a contraindication to MR imaging, such as implanted metal devices or foreign bodies
10. Patient must not have a contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
11. Patient must not have other metastatic malignancies requiring current active treatment
12. Patient must not have any severe active comorbidities, defined as follows:

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (446 Sites)

Showing the first 25 of 446 sites.

• University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
• Katmai Oncology Group — Anchorage, Alaska
• Fairbanks Memorial Hospital — Fairbanks, Alaska
• University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• City of Hope Corona — Corona, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• Veterans Affairs Loma Linda Healthcare System — Loma Linda, California
• Tibor Rubin VA Medical Center — Long Beach, California
• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• Veterans Affairs Medical Center - San Francisco — San Francisco, California
• City of Hope South Pasadena — South Pasadena, California
• Rocky Mountain Regional VA Medical Center — Aurora, Colorado
• UCHealth University of Colorado Hospital — Aurora, Colorado
• UCHealth Memorial Hospital Central — Colorado Springs, Colorado
• Memorial Hospital North — Colorado Springs, Colorado
• Poudre Valley Hospital — Fort Collins, Colorado
• Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
• Banner North Colorado Medical Center — Greeley, Colorado
• UCHealth Greeley Hospital — Greeley, Colorado
• UCHealth Highlands Ranch Hospital — Highlands Ranch, Colorado
• Saint Anthony Hospital — Lakewood, Colorado
• Medical Center of the Rockies — Loveland, Colorado

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive Stage Lung Small Cell Carcinoma

• Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer — Buffalo, New York
• LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer — Duarte, California
• Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker — Anchorage, Alaska
• Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial — Houston, Texas
• Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer — Duarte, California

Explore by condition: All Extensive Stage Lung Small Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.